Indicators on BCAT-IN-4 You Should Know
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre review to evaluate many intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Primary trial aims were to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyositis patie